Trevi Therapeutics, Inc.
TRVI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,327,711 | $713,017 | $739,772 | $436,760 |
| - Cash | $56,869 | $117,058 | $19,374 | $34,097 |
| + Debt | $823 | $891 | $957 | $1,032 |
| Enterprise Value | $1,271,665 | $596,850 | $721,355 | $403,695 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | -$38 |
| % Margin | – | – | – | – |
| EBITDA | -$11,779 | -$12,284 | -$10,314 | -$11,360 |
| % Margin | – | – | – | – |
| Net Income | -$11,802 | -$12,301 | -$10,340 | -$11,415 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.08 | -0.094 | -0.088 | -0.11 |
| % Growth | 15.3% | -7.4% | 20.1% | – |
| Operating Cash Flow | -$10,880 | -$10,101 | -$13,477 | -$9,550 |
| Capital Expenditures | -$12 | $0 | $0 | -$7 |
| Free Cash Flow | -$10,892 | -$10,101 | -$13,477 | -$9,557 |